Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: similarities and difference in the metabolism of pitavastatin in monkeys and humans

References

• AOKI, T., YOSHINAKA, Y., YAMAZAKI, H., SUZUKI, H., TAMAKI, T., SATO, F., KITAHARA, M. and SAITO, Y., 2002, Triglyceride-lowering effect of pitvastatin in a rat model of postprandial lipemia. European Journal of Pharmacology, 444, 107–113.
   PubMedGoogle Scholar
• BABA, S., TERASAWA, Y., KIMATA, H., SHINOHARA, Y., AKIRA, K. and HASEGAWA, H., 1994, Application of radioluminography to off-line counting of radioactivity in high-performance liquid chromatographic elutes. Journal of Chromatography (A), 663, 35–41.
   Web of Science ®Google Scholar
• BROWN, B. G., ZHAO, X. Q., SACCO, D. E. and ALBERS, J. J., 1993, Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation, 87, 1781–1791.
   PubMed Web of Science ®Google Scholar
• CHIBA, M., NISHIME, J. A., NEWAY, W., LIN, Y. and LIN, J. H., 2000, Comparative in vitro metabolism of indinavir in primates - a unique stereoselective hydroxylation in monkey. Xenobiotica, 30, 117–129.
   PubMed Web of Science ®Google Scholar
• FUJINO, H., KOJIMA, J., YAMADA, Y., KANDA, H. and KIMATA, H., 1999b, Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4):Interspecies variation in laboratory animals and humans. Xenobiotic Metabolism and Disposition, 14, 79–91.
   Google Scholar
• FUJIN°, H., YAMADA, I., KOJIMA, J., HIRANO, M., MATSUMOTO, H. and YONEDA, M., 1999a, Studies on the metabolic fate of NK-104, a new inhibitor HMG-CoA reductase (5): In vitro metabolism and plasma protein binding in animals and human. Xenobiotic Metabolism and Disposition, 14, 415–424.
   Google Scholar
• FUJIN°, H., YAMADA, I., SHIMADA, S. and YONEDA, M., 2001, Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin layer chromatography assay-inhibitory effect of NK-104, a new inhibitor of HMG-CoA reductase. Journal of Chromatography ( B), 757, 143–150.
   PubMedGoogle Scholar
• FUJINO, H., YAMADA, I., SHIMADA, S. and YONEDA, M., 2002, The metabolic fate of pitavastatin (NK-104), a new inhibitor of HMG-CoA reductase: Effects on drug-metabolizing systems in rats and humans. Arzneimittel Forschungl Drug Research, 52, 745–753.
   PubMed Web of Science ®Google Scholar
• FUPNO, H., YAMADA, I., SHIMADA, S., YONEDA, M and KOJIMA, J., 2003, The metabolic fate of pitavastatin (NK-104), a new inhibitor of HMG-CoA reductase-human UDP-glucuronosyl-transferase isoforms involved in the lactonization of pitavastatin. Xenobiotica, 33, 27–41.
   Google Scholar
• HAVEL, R. J. and RAPAPORT, E., 1995, Management of primary hyperlipidemia. New England Journal of Medicine, 332, 1301–1307.
   Web of Science ®Google Scholar
• JACOBSEN, W., KUHN, B., SOLDNER, A., KIRCHNER, G., SEWING, K. F., KOLLMAN, P. A., BENET, L. Z. and CHRISTIANS, U., 2000, Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metabolism and Disposition, 28, 1369–1378.
   PubMed Web of Science ®Google Scholar
• KAJINAMI, K., Komumi, J., UEDA, K., MIYAMOTO, S., TAKEGOSHI, T. and MABUCHI, H. 2000b, Effect of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 study group. American Journal of Cardiology, 15, 178–183.
   Web of Science ®Google Scholar
• KAJINAMI, K., MABUCHI, H. and SAITO, Y., 2000a, NK-104: a novel synthetic HMG-CoA reductase inhibitor. Expert Opinion on Investigational Drugs, 9, 2653–2661.
   PubMed Web of Science ®Google Scholar
• KIMATA, H., FUJINO, H., KOIDE, T., YAMADA, Y., TSUNENARI, Y., YONEMITSU, M. and YANAGAWA, Y., 1998, Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats. Xenobiotic Metabolism and Disposition, 13, 484–498.
   Google Scholar
• KOJIMA, J., FUJINO, H., ABE, H., YOSHIMURA, M., KANDA, H. and KIMATA, H., 1999a, Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Biology and Pharmacology Bulletin, 22, 142–150.
   PubMed Web of Science ®Google Scholar
• KOJIMA, J., FUJIN°, H., YOSHIMURA, M., MORIKAWA, H. and KIMATA, H., 1999b, Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. journal of Chromatography (B), 724, 173–180.
   Google Scholar
• PRUEKSARITANONT, T., SUBRAMANIAN, R., FANG, X., MA, B., Qiu, Y., LIN, J. H., PEARSON, P. G. and BAILLIE, T. A., 2002, Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metabolism and Disposition, 30, 505–512.
   PubMed Web of Science ®Google Scholar
• SAITO, Y YAMADA, N., TERAMOTO, T., ITAKURA, H., HATA, Y., NAKAYA, N., MABUCHI, H., TUSHIMA, M., SASAKI, J., GOTO, Y. and OGAWA, N., 2002, Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittel ForschunglDrug Research, 52, 251–255.
   Google Scholar
• STIZUM, H., YAMAZAKI, H., Aoxt, T. and TAMAKI, T., 2001, Hypolipidemic effect of NK-104 and other 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in guinea pigs. Arzneimittel ForschunglDrug Research, 51, 38–45.
   PubMedGoogle Scholar
• SUZUKI, H., YAMAZAKI, H., AOKI, T., KOJIMA, J., TAMAKI, T., SATO, F., KITAHARA, M. and SAITO, Y., 2000, Lipid-lowering and antiatherosclerotic effect of NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits. Arzneimittel ForschunglDrug Research, 50, 995–1003.
   PubMedGoogle Scholar
• WEAVER, R. J., DICKINS, M. and BURKE, M. D., 1999, A comparison of basal and induced hepatic microsomal cytochrome P450 monooxygenase activities in the cynomolgus monkey (Macaca fascicularies) and man. Xenobiotica, 29, 467–482.
   PubMed Web of Science ®Google Scholar
• XIE, R., MATHIJSSEN, R. H., SPARREBOOM, A., VERWEIJ, J. and KARLSSON, M. 0., 2002, Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. Journal of Clinical Oncology, 20, 3293–3301.
   Google Scholar